Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
09/2000
09/06/2000EP0504388B1 Varicella-zoster virus antigen
09/06/2000CN1265598A Method for treating thrombotic disorders
09/06/2000CN1265583A Aqueous aerosol preparations containing biologically active macromolecules and method for producing the corresponding aerosols
09/06/2000CN1265327A Making process of subunit antigen vaccine cream
09/06/2000CN1265326A Triple live chicken vaccine and its production process
09/06/2000CN1056085C Tocols as adjuvant in vaccine
09/06/2000CN1056084C Immunotoxins directed against CD33 related surface antigens
09/05/2000US6114598 Generation of xenogeneic antibodies
09/05/2000US6114516 Nucleotide sequences coding for variable regions of the αchains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic muses
09/05/2000US6114515 PIGRL-1, a member of immunoglobulin gene superfamily
09/05/2000US6114506 Composition and method for enhancing fibrinolysis
09/05/2000US6114323 Diabetic kidney disease; administering aminoguanidine
09/05/2000US6114142 Parasitic helminth nucleic acid molecules/and uses thereof
09/05/2000US6114131 Methods for the detection of antibodies to ornithobacterium rhinotracheale
09/05/2000US6114125 Analog of Haemophilus Hin47 with reduced protease activity
09/05/2000US6114110 Isolation and propagation of a human herpesvirus derived from AIDS-associated Kaposi's sarcoma cells
09/05/2000US6114108 Methods and compositions for the selective modification of viral nucleic acids
09/05/2000US6113918 Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
09/05/2000US6113917 Genetic polypeptides added to ceramide based lipid-glycan anchor structure
09/05/2000US6113916 Vaccine for response to mycoplasma in swine
09/05/2000US6113914 Osp A proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
09/05/2000US6113913 Genomes and gene codes
09/05/2000US6113912 Hepatitis A virus vaccines
09/05/2000US6113911 Peptide fragment of respiratory syncytial virus protein G, immunogenic agent, pharmaceutical composition containing it and preparation method
09/05/2000US6113910 Vaccines for gastroenteritis in humans
09/05/2000US6113905 Borna disease viral sequences, diagnostics and therapeutics for nervous system diseases
09/05/2000US6113903 Antidiabetic agents
09/05/2000US6113902 Polypeptides with amino acid sequences of pro-lys-ile and cyclic epitopes
09/05/2000US6113901 Immunopotentiating cd-3 antigen monoclonal antibodies
09/05/2000US6113899 Antagonists of chaperonin 10
09/05/2000US6113898 Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
09/05/2000US6113897 Antibodies and their use
08/2000
08/31/2000WO2000050897A1 Compounds and methods for the detection and prevention of t. cruzi infection
08/31/2000WO2000050619A1 Adenovirus mutants with deleted protease gene, complementing cell lines and corresponding vectors for gene transfer
08/31/2000WO2000050618A1 Virus vector
08/31/2000WO2000050608A1 Novel polypeptide
08/31/2000WO2000050607A2 Goodpasture antigen binding protein
08/31/2000WO2000050600A1 Pheromones derived from clostridium species
08/31/2000WO2000050599A1 Haemophilus antigen
08/31/2000WO2000050590A1 Mdm interacting protein and methods of use thereof
08/31/2000WO2000050584A2 Methods and compositions for enhancing in vivo gene delivery/expression
08/31/2000WO2000050580A2 Composition, methods and reagents for the synthesis of a soluble form of human phex
08/31/2000WO2000050562A2 Dna encoding snorf25 receptor
08/31/2000WO2000050460A1 Epitopes or mimotopes derived from the c-epsilon-2 domain of ige, antagonists thereof, and their therapeutic uses
08/31/2000WO2000050455A2 Antigen to systemic lupus erythematosis and diagnostic assay
08/31/2000WO2000050453A1 A novel inhibitor of programmed cell death
08/31/2000WO2000050443A2 Secreted proteins and uses thereof
08/31/2000WO2000050080A1 Compositions and methods using complexes of calreticulin and antigenic molecules
08/31/2000WO2000050078A1 Use of bioadhesives and adjuvants for the mucosal delivery of antigens
08/31/2000WO2000050075A2 Enhancement of bactericidal activity of neisseria antigens with oligonucleotides containing cg motifs
08/31/2000WO2000050074A2 Neisserial vaccine compositions and methods
08/31/2000WO2000050073A2 Caulobacter lps immunoadjuvant
08/31/2000WO2000050072A2 Method for the purification, recovery, and sporulation of cysts and oocysts
08/31/2000WO2000050071A1 PROTEIN OmpA OF KLEBSIELLA PNEUMONIAE ASSOCIATED WITH THE HCG HORMONE OR A COMPOUND INVOLVED IN CELL PROLIFERATION OR FERTILITY
08/31/2000WO2000050044A1 Vaccine for house dust mite allergen using naked plasmid dna
08/31/2000WO2000032632A3 Allo- and auto-reactive t-cell epitopes from rhesus protein and their use
08/31/2000WO2000028040A3 Cloning of rhadinovirus genome and methods for its use
08/31/2000WO2000028038A3 Virulence genes and proteins, and their use
08/31/2000WO2000028029A3 Cell surface glycoproteins
08/31/2000WO2000027410A3 Composition and method for increasing weight gain and feed efficiency
08/31/2000WO2000026236A3 Method of modulating cell differentiation or neoplastic transformation by altering cadherin-11 expression or function
08/31/2000WO2000020584A9 Human gene expressed in cancers of prostate, bladder, pancreas and colon, 36p1a6
08/31/2000WO2000018910A9 Moraxella catarrhalis protein, nucleic acid sequence and uses thereof
08/31/2000WO2000018906A9 Shuffling of codon altered genes
08/31/2000WO2000018803A3 Antibodies to mammalian langerhans cell antigen and their uses
08/31/2000WO2000018795A9 Compositions and methods for wt1 specific immunotherapy
08/31/2000WO2000015238B1 COMPOSITIONS OF β-GLUCANS AND SPECIFIC IGIV
08/31/2000CA2710788A1 Method for the purification, recovery, and sporulation of cysts and oocysts
08/31/2000CA2689696A1 Microemulsions with adsorbed macromolecules and microparticles
08/31/2000CA2371928A1 Neisserial vaccine compositions and methods
08/31/2000CA2366688A1 Use of bioadhesives and adjuvants for the mucosal delivery of antigens
08/31/2000CA2365026A1 Virus vector
08/31/2000CA2365019A1 Novel polypeptide
08/31/2000CA2363829A1 Haemophilus antigen
08/31/2000CA2363637A1 Epitopes or mimotopes derived from the c-epsilon-2 domain of ige, antagonists thereof, and their therapeutic uses
08/31/2000CA2363621A1 A novel inhibitor of programmed cell death
08/31/2000CA2363146A1 Caulobacter lps immunoadjuvant
08/31/2000CA2363106A1 Mdm interacting protein and methods of use thereof
08/31/2000CA2362928A1 Vaccine for house dust mite allergen using naked plasmid dna
08/31/2000CA2362906A1 Dna encoding snorf25 receptor
08/31/2000CA2362608A1 Compounds and methods for the detection and prevention of t. cruzi infection
08/30/2000EP1031835A1 Diagnostic, prognostic, and therapeutic methods for solid non-lymphoid tumors and their metastases.
08/30/2000EP1031347A1 Transnasal transport/immunisation with highly adaptable carriers
08/30/2000EP1031346A1 Noninvasive vaccination through the skin
08/30/2000EP1030927A1 Expression plasmids for multiepitope nucleic acid-based vaccines
08/30/2000EP1030923A2 Method for producing virus-like particles on the basis of polyoma viruses
08/30/2000EP1030919A2 Cdk2 protein and cdk2 protein complexes
08/30/2000EP1030917A1 Transcriptionally regulated g protein-coupled receptor
08/30/2000EP1030916A2 Differentially expressed genes in cardiac hypertrophy and their uses in treatment and diagnosis
08/30/2000EP1030915A1 A novel gene and uses therefor
08/30/2000EP1030911A1 Human aspartic proteases
08/30/2000EP1030865A2 Th2 CELL DEPLETION; COMPOSITIONS; METHODS
08/30/2000EP1030862A1 Viral clearance process
08/30/2000EP1030861A1 Modification of virus tropism and host range by viral genome shuffling
08/30/2000EP1030819A1 Immunogenic conjugated polypeptide for treatment of herpes simplex virus
08/30/2000EP1030690A1 Recombinant vaccines comprising immunogenic attenuated bacteria having rpos positive phenotype
08/30/2000EP1030684A1 Modified antibodies with enhanced ability to elicit an anti-idiotype response
08/30/2000EP1030683A1 Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions
08/30/2000EP1030675A2 Treatment of hematologic disorders
08/30/2000EP1030674A1 METHODS FOR TREATMENT OF TUMORS AND TUMOR CELLS USING $i(EX VIVO) ACTIVATED T CELLS
1 ... 1460 1461 1462 1463 1464 1465 1466 1467 1468 1469 1470 1471 1472 1473 1474 1475 1476 1477 1478 1479 1480 ... 1823